(NASDAQ: IONS) Ionis Pharmaceuticals's forecast annual revenue growth rate of 25.48% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.03%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.96%.
Ionis Pharmaceuticals's revenue in 2026 is $1,058,189,000.On average, 28 Wall Street analysts forecast IONS's revenue for 2026 to be $150,635,167,168, with the lowest IONS revenue forecast at $141,254,864,490, and the highest IONS revenue forecast at $169,559,382,456. On average, 28 Wall Street analysts forecast IONS's revenue for 2027 to be $238,804,393,420, with the lowest IONS revenue forecast at $186,250,900,612, and the highest IONS revenue forecast at $352,670,294,504.
In 2028, IONS is forecast to generate $350,191,356,164 in revenue, with the lowest revenue forecast at $280,946,345,200 and the highest revenue forecast at $474,468,798,276.